Vitreoretinal Interface Changes After Anti-vascular Endothelial Growth Factor Treatment in Highly Myopic Eyes: A Real-World Study

Mei Chi Tsui, Yi Ting Hsieh, Tso Ting Lai, Yun Hsia, Shih Wen Wang, I. Hsin Ma, Kuo Chi Hung, Chang Pin Lin, Chang Hao Yang, Chung May Yang, Tzyy Chang Ho

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Introduction: To investigate changes in the vitreoretinal interface after anti-vascular endothelial growth factor (anti-VEGF) treatment in highly myopic eyes. Methods: Eyes with myopic choroidal neovascularization (mCNV) treated with intravitreal injection of anti-VEGF in a single-center were retrospectively reviewed. Fundus abnormalities and features of optical computed tomography were studied. Results: A total of 295 eyes from 254 patients were recruited to the study. Prevalence of myopic macular retinoschisis (MRS) was 25.4%, and the rates of progression and onset of MRS were 75.9% and 16.2%, respectively. Outer retinal schisis (β = 8.586, p = 0.003) and lamellar macular hole (LMH) (β = 5.015, p = 0.043) at baseline were identified risk factors for progression and onset of MRS, whereas male sex (β = 9.000, p = 0.039) and outer retinal schisis at baseline (β = 5.250, p = 0.010) were risk factors for MRS progression. Progression of MRS was first detected in outer retinal layers in 48.3% of eyes. Thirteen eyes required surgical intervention. Spontaneous improvements of MRS were observed in five eyes (6.3%). Conclusion: Changes in the vitreoretinal interface, such as progression, onset, and improvement of MRS, were observed after anti-VEGF treatment. Outer retinal schisis and LMH were risk factors of progression and onset of MRS after anti-VEGF treatment. Intravitreal injection of ranibizumab and retinal hemorrhage were protective factors for surgical intervention for vision-threatening MRS.

Original languageEnglish
Pages (from-to)1693-1710
Number of pages18
JournalOphthalmology and Therapy
Issue number3
Publication statusPublished - Jun 2023


  • Anti-vascular endothelial growth factor
  • High myopia
  • Myopic choroidal neovascularization
  • Myopic macular retinoschisis
  • Myopic traction maculopathy
  • Vitreoretinal interface

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Vitreoretinal Interface Changes After Anti-vascular Endothelial Growth Factor Treatment in Highly Myopic Eyes: A Real-World Study'. Together they form a unique fingerprint.

Cite this